Diabetic Nephropathy Market is expected to show positive growth, during the forecast period of 2019 to 2032, as per DelveInsight

July 27 18:04 2022
Diabetic Nephropathy Market is expected to show positive growth, during the forecast period of 2019 to 2032, as per DelveInsight

Diabetic Nephropathy Market Insights report from DelveInsight provides a thorough understanding of the Diabetic Nephropathy Market size by treatment, epidemiology, emerging therapies, market share of the various therapies, and the current and forecasted Diabetic Nephropathy Market size from 2019 to 2032 divided into the 7MM (the USA, EU5 (Germany, France, Italy, Spain, and the UK), and Japan) regions.


Diabetic Nephropathy Overview

Diabetic nephropathy is a long-term kidney disease that can affect people with diabetes. It is also known as Diabetic Kidney Disease (DKD). It happens when a person’s kidneys are damaged by elevated blood glucose levels.


Download Sample Report- https://www.delveinsight.com/sample-request/diabetic-nephropathy-market


Regions covered in the report

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan


Key highlights of the Diabetic Nephropathy Market

  • According to DelveInsight, Diabetic Nephropathy affects males more than the females.
  • As per the DelveInsight analysis, the EU5 countries accounted for over 10 million prevalent cases of Diabetic Nephropathy in 2021 which is expected to increase in during the study period [2019–2032]. Among the EU5 countries, Germany had the highest number of prevalent cases of Diabetic Nephropathy which were approximately 5.2 million cases in 2021.
  • In the United States, highest cases of Diabetic Nephropathy were found in Stage 3a which were ~4.7 million in 2021, followed by ~3.1 million cases in stage 1 and 2.7 million cases in stage 2. Among all the stages, stage 5 reported least number of cases (~215k).


Diabetic Nephropathy Epidemiology Insights

The prevalence of diabetes worldwide has extended epidemic magnitudes and is expected to affect millions of people in the upcoming years. Diabetic nephropathy is the leading cause of chronic kidney disease (CKD) in the United States and other Western societies. It is also one of the most significant long-term complications in terms of morbidity and mortality for individual patients with diabetes.


Diabetic Nephropathy Epidemiology Segmentation in the 7MM

  • Diabetic Nephropathy Stage-specific prevalence
  • Diabetic Nephropathy Age-specific prevalence
  • Total Diabetic Nephropathy prevalence
  • Diabetic Nephropathy Prevalence
  • Diabetic Nephropathy Gender-specific prevalence


Do you want to know more information related to the report? If yes, visit here- https://www.delveinsight.com/sample-request/diabetic-nephropathy-market


Diabetic Nephropathy Market Insights

Diabetic nephropathy (DN) is a clinical syndrome characterized by persistent albuminuria and a progressive decline in renal function, and the term infers the presence of a typical pattern of glomerular disease. DN is strongly associated with CV events and has a major influence on survival. The cornerstone of therapy in patients with albuminuria is hypertensive control, angiotensin-converting enzyme (ACE) inhibitors, or angiotensin receptor blockers (ARB), which slow down the rate of kidney function decline. However, they do not reduce the number of cardiovascular events. In addition, glycemic control is essential to delay or possibly prevent nephropathy and the onset of complications from diabetes, which can be challenging for even the most experienced physician.


Diabetic Nephropathy Treatment Market

Among novel treatments, mineralocorticoid receptor antagonists (MRA) are considered extremely promising. The first oral MRA was spironolactone followed by eplerenone; both are steroidal MRA. These drugs are often used off-label in T2DM patients with mild-to-moderate arterial hypertension and albuminuria. However, the risk of the development of hyperkalemia with their usage remains a pressing issue. Recently, the FDA has approved finerenone (Kerendia, Bayer) to treat adult patients with CKD associated with T2D.


Diabetic Nephropathy Market Size

Advances in disease mechanisms have yielded new diagnostic and therapeutic approaches, opening the way to more medicine development. The market is expected to show positive growth, mainly attributed to the increased diagnosed prevalence and also, the launch of upcoming therapies during the forecast period.


Diabetic Nephropathy Risk Factors

The risk factors for diabetic nephropathy incorporate smoking, comorbidities and is more prevalent in people who are more than 62-65 years old. An individual with diabetic nephropathy may not experience any symptoms in the early stages. Changes in blood pressure and fluid equilibrium in the body, on the other hand, may already be present. Waste products can accumulate in the blood over time, causing symptoms. Swollen feet and ankles, darker urine, shortness of breath are some of the symptoms presented in the later stages.


Request Sample Report- https://www.delveinsight.com/sample-request/diabetic-nephropathy-market


Table of Content

1. Key Insights

2. Diabetic Nephropathy Executive Summary

3. Diabetic Nephropathy Competitive Intelligence Analysis

4. Diabetic Nephropathy: Market Overview at a Glance

5. Diabetic Nephropathy: Disease Background and Overview

6. Patient Journey

7. Diabetic Nephropathy Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Diabetic Nephropathy Unmet Needs

10. Key Endpoints of Diabetic Nephropathy Treatment

11. Diabetic Nephropathy Marketed Products

12. Diabetic Nephropathy Emerging Therapies

13. Diabetic Nephropathy: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview

17. KOL Views

18. Diabetic Nephropathy Market Drivers

19. Diabetic Nephropathy Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight


Diabetic Nephropathy Market Report Highlights

  • In the coming years, the Diabetic Nephropathy market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Diabetic Nephropathy R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition     
  • Major players are involved in developing therapies for Diabetic Nephropathy. The launch of emerging therapies will significantly impact the Diabetic Nephropathy market
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Diabetic Nephropathy
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities


Why should you buy this report?

  • The report will help in developing business strategies by understanding trends shaping and driving the Diabetic Nephropathy market
  • To understand the future market competition in the Diabetic Nephropathy market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Diabetic Nephropathy in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Diabetic Nephropathy market
  • To understand the future market competition in the Diabetic Nephropathy market


About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/